

Oncology Injectable and Infused Medication Enrollment Form



Fax Referral To: 1-877-232-5455
Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813

Phone: 1-808-254-2727
NCPDP: 1203417

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: _____ DOB: _____ Gender: Male Female
Address: _____ City, State, ZIP Code: _____
Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)
Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
Primary Phone: _____ Alternate Phone: _____
Email: _____ Last Four of SSN: _____ Primary Language: _____
Parent/Caregiver/Legal Guardian Name (Last, First): _____ Relationship to Patient: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____
NPI #: _____ DEA #: _____ Group or Hospital: _____
Address: _____ City, State, ZIP Code: _____
Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: Patient Office Other: _____

Diagnosis (ICD-10):

Code: _____ Description: _____ Code: _____ Description: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ in/cm BSA: _____ m²

Oncology Injectable and Infused Medication Enrollment Form

A-K

Please complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____ Patient Phone: _____

Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

Medications:

- | | | | |
|--|---|---|---|
| <input type="checkbox"/> Abraxane
(nab-paclitaxel) | <input type="checkbox"/> (irinotecan) | <input type="checkbox"/> Empliciti
(elotuzumab) | <input type="checkbox"/> Imjudo
(tremelimumab-actl) |
| <input type="checkbox"/> Adcetris
(brentuximab vedotin) | <input type="checkbox"/> Carboplatin | <input type="checkbox"/> Enhertu
(fam-trastuzumab
deruxtecan-nxki) | <input type="checkbox"/> Irinotecan |
| <input type="checkbox"/> Alimta
(pemetrexed) | <input type="checkbox"/> Cisplatin | <input type="checkbox"/> Erbitux
(cetuximab) | <input type="checkbox"/> Istodax
(romidepsin) |
| <input type="checkbox"/> Alymsys
(bevacizumab-maly) | <input type="checkbox"/> Cladribine | <input type="checkbox"/> Erwinaze
(asparaginase Erwinia
chrysanthemii) | <input type="checkbox"/> Ixempra
(ixabepilone) |
| <input type="checkbox"/> Arranon
(nelarabine) | <input type="checkbox"/> Columvi
(glofitamab-gxbl) | <input type="checkbox"/> Etoside | <input type="checkbox"/> Jemperli
(dostarlimab-gxly) |
| <input type="checkbox"/> Asparlas
(calaspargase pegol-mknl) | <input type="checkbox"/> Cyclophosphamide | <input type="checkbox"/> Fludarabine | <input type="checkbox"/> Jevtana
(cabazitaxel) |
| <input type="checkbox"/> Avastin
(bevacizumab) | <input type="checkbox"/> Cyramza
(ramucirumab) | <input type="checkbox"/> Fluorouracil | <input type="checkbox"/> Kadcyra
(ado-trastuzumab emtansine) |
| <input type="checkbox"/> Beleodaq
(belinostat) | <input type="checkbox"/> Cytarabine | <input type="checkbox"/> Gazyva
(obinutuzumab) | <input type="checkbox"/> Keytruda
(pembrolizumab) |
| <input type="checkbox"/> Belrapzo
(bendamustine) | <input type="checkbox"/> Dacarbazine | <input type="checkbox"/> Gemcitabine HCL
(trastuzumab) | <input type="checkbox"/> Kanjinti
(trastuzumab-anns) |
| <input type="checkbox"/> Bendeka
(bendamustine) | <input type="checkbox"/> Dactinomycin | <input type="checkbox"/> Herceptin
(trastuzumab) | <input type="checkbox"/> Kyprolis
(carfilzomib) |
| <input type="checkbox"/> Besponsa
(inotuzumab ozogamicin) | <input type="checkbox"/> Darzalex
(daratumumab) | <input type="checkbox"/> Herceptin Hylecta
(trastuzumab and
hyaluronidase-oysk) | |
| <input type="checkbox"/> BiCNU
(carmustine) | <input type="checkbox"/> Darzalex Faspro
(daratumumab and
hyaluronidase-fihj) | <input type="checkbox"/> Herzuma
(trastuzumab-pkrb) | |
| <input type="checkbox"/> Bleomycin | <input type="checkbox"/> Daunorubicin | <input type="checkbox"/> Ifosfamide | |
| <input type="checkbox"/> Camptosar | <input type="checkbox"/> Decitabine | <input type="checkbox"/> Imfinzi
(durvalumab) | |
| | <input type="checkbox"/> Dexrazoxane | | |
| | <input type="checkbox"/> Doxorubicin | | |
| | <input type="checkbox"/> Doxorubicin liposomal | | |
| | <input type="checkbox"/> Elitek
(rasburicase) | | |

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 2	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 3	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

Oncology Injectable and Infused Medication Enrollment Form

L-Z

Please complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____ Patient Phone: _____

Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

Medications:

- | | | | |
|---|--|--|--|
| <input type="checkbox"/> Leucovorin | <input type="checkbox"/> (pertuzumab) | <input type="checkbox"/> (isatuximab-irfc) | <input type="checkbox"/> Vidaza |
| <input type="checkbox"/> Levoleucovorin | <input type="checkbox"/> Phesgo | <input type="checkbox"/> Sylvant | (azacitidine) |
| <input type="checkbox"/> Lunsumio | (pertuzumab, trastuzumab, and | <input type="checkbox"/> Siltuximab | <input type="checkbox"/> Vinblastine |
| (mosunetuzumab-axgb) | hyaluronidase-zzxf) | <input type="checkbox"/> Tecentriq | <input type="checkbox"/> Vincristine |
| <input type="checkbox"/> Margenza | <input type="checkbox"/> Polivy | (atezolizumab) | <input type="checkbox"/> Vinorelbine |
| (margetuximab-cmkb) | (polatuzumab vedotin-piiq) | <input type="checkbox"/> Temsirolimus | <input type="checkbox"/> Vyxeos |
| <input type="checkbox"/> Melphalan | <input type="checkbox"/> Portrazza | <input type="checkbox"/> Thyrogen | (daunorubicin/cytarabine |
| <input type="checkbox"/> Mesna | (necitumumab) | (thyrotropin alfa) | (liposomal)) |
| <input type="checkbox"/> Mitomycin | <input type="checkbox"/> Poteligeo (mogamulizumab- | <input type="checkbox"/> Tice BCG | <input type="checkbox"/> Xgeva |
| <input type="checkbox"/> Mvasi | kpkc) | (bacillus calmette-guerin live) | (denosumab) |
| (bevacizumab-awwb) | <input type="checkbox"/> Proleukin | <input type="checkbox"/> Tivdak | <input type="checkbox"/> Yervoy |
| <input type="checkbox"/> Mylotarg | (aldesleukin, IL-2) | (tisotumab vedotin-tftv) | (ipilimumab) |
| (gemtuzumab ozogamicin) | <input type="checkbox"/> Riabni | <input type="checkbox"/> Topotecan | <input type="checkbox"/> Yondelis |
| <input type="checkbox"/> Onivyde | (rituximab-arrx) | <input type="checkbox"/> Trazimera | (trabectedin) |
| (irinotecan liposomal) | <input type="checkbox"/> Rituxan | (trastuzumab-qyyp) | <input type="checkbox"/> Zaltrap |
| <input type="checkbox"/> Ontruzant | (rituximab) | <input type="checkbox"/> Treanda | (ziv-aflibercept) |
| (trastuzumab-dttb) | <input type="checkbox"/> Rituxan Hycela | (bendamustine) | <input type="checkbox"/> Zepzelca |
| <input type="checkbox"/> Opdivo | (rituximab | <input type="checkbox"/> Trisenox | (lurbinectedin) |
| (nivolumab) | and hyaluronidase human) | (arsenic trioxide) | <input type="checkbox"/> Zirabev |
| <input type="checkbox"/> Opdualag | <input type="checkbox"/> Ruxience | <input type="checkbox"/> Truxima | (bevacizumab-bvzr) |
| (nivolumab and | (rituximab-pvvr) | (rituximab-abbs) | <input type="checkbox"/> Zoledronic Acid |
| relatimab-rmbw) | <input type="checkbox"/> Rybrevant | <input type="checkbox"/> Valrubicin | <input type="checkbox"/> Other: _____ |
| <input type="checkbox"/> Oxaliplatin | (amivantamab-vmjw) | <input type="checkbox"/> Vectibix | |
| <input type="checkbox"/> Paclitaxel | <input type="checkbox"/> Rylaze | (panitumumab) | |
| <input type="checkbox"/> Padcev | (asparaginase erwinia | <input type="checkbox"/> Vegzelma | |
| (enfortumab vedotin-ejfv) | chrysanthemi-rywn) | (bevacizumab-adcd) | |
| <input type="checkbox"/> Pamidronate | | <input type="checkbox"/> Velcade | |
| <input type="checkbox"/> Perjeta | <input type="checkbox"/> Sarclisa | (bortezomib) | |

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 2	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 3	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.